About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Chapters
Books
News
Editorials
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Scientometrics
Impact Factor
Discipline Ranks
H-Index
G-Index
Articles
Citations
Article Citations
Citation Distribution
Search This Journal
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
exaly
›
Journals
›
Clinical Cancer Research
›
Top Articles
Clinical Cancer Research
Oncology
12.9
(top 1%)
Impact Factor
13.7
(top 1%)
extended IF
338
(top 1%)
H-Index
15.2K
authors
19.4K
papers
1.3M
citations
9.8K
citing journals
245.8K
citing authors
Most Cited Articles of Clinical Cancer Research
Title
Year
Citations
Triple-negative breast cancer: clinical features and patterns of recurrence
2007
3K
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria
2009
2.4K
Therapeutic nanoparticles for drug delivery in cancer
2008
2.2K
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
2004
2.2K
X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization
2004
2K
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases
2004
1.9K
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer
2008
1.7K
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy
2014
1.7K
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers
2013
1.7K
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes
2007
1.5K
Clinical features of metastatic bone disease and risk of skeletal morbidity
2006
1.5K
The interleukin-8 pathway in cancer
2008
1.5K
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy
2011
1.4K
Breast cancer molecular subtypes respond differently to preoperative chemotherapy
2005
1.4K
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship
2003
1.4K
Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system
2007
1K
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome
2008
1K
Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody
2009
1K
Phase II trial of curcumin in patients with advanced pancreatic cancer
2008
997
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research
2009
960
CXCL12 (SDF-1)/CXCR4 pathway in cancer
2010
953
Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance
2004
933
Prostate-specific membrane antigen expression in normal and malignant human tissues
1997
927
Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype
2008
917
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
2007
896
previous
2010
2011
2012
How are inpact factors calculated?
The impact factor (IF) is calculated by counting citations from peer-reviewed journals only.
extended IF
also counts citations from books and conference papers. However, no patent, abstract, working papers, online documents, etc., are covered.
site/software ©
exaly
; All materials licenced under
CC by-SA
.